阿立哌唑治疗首发精神分裂症的疗效评价与安全性分析

Evaluation of curative effects and safety of aripiprazole in the treatment of patients with first-episode schizophrenia

目的评估阿立哌唑治疗首发精神分裂症的临床疗效和安全性。方法将80例首发精神分裂症患者随机分为阿立哌唑组和利培酮组(各40例),治疗前后分别评定阳性及阴性症状量表(PANSS),以PANSS减分率评定疗效,副反应量表(TESS)及实验室相关检查评定药物副反应。结果治疗8周后,两组PANSS各项评分较治疗前均显著降低(P<0.05),两组PANSS各项评分减分比较差异均无统计学意义(P>0.05);阿立哌唑组总有效率为72.5%,对照组总有效率为70.0%,两组总有效率比较差异无统计学意义(P>0.05);两组均未发生严重相关不良事件。结论阿立哌唑是一种安全有效的抗精神病药物,对首发精神分裂症的疗效与利培酮相当。

Objective To assess the efficacy and safety of aripiprazole in the treatment of first-episode schiz- ophrenia. Methods Eighty patients with first-episode schizophrenia were randomized into afipiprazole group （ n = 40 ） and rispefidone group （n = 40）. The positive and negative syndrome scale （PANSS） and treatment emergent symptom scale （TESS） were used to assess the effectiveness and the safety of the treatment. Results The scores of PANSS de- creased significantly comparing to the base line in both groups （ P 〈 0. 05 ） and without statistically difference between two groups （ P 〉 0. 05 ） by the end of the 8 weeks treatment ;There is no marked difference between two groups in the decrease of all elements of PANSS after 8-week treatment（P 〉0. 05） ; The total efficacious rate of aripiprazole group was 72.5% and that of risperidone group was 70. 0% , the secondary reaction of two groups was less. Conclusion Aripiprazole is a safe and effeetive antipsyehoties, it has similar efficacy to risperidon in the antipsychotic treatment.